LIGAND PHARMACEUTICALS INCLGNDEarnings & Financial Report
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also own...
LGND Q4 FY2025 Key Financial Metrics
Revenue
$59.7M
Gross Profit
N/A
Operating Profit
$13.8M
Net Profit
$44.8M
Gross Margin
N/A
Operating Margin
23.2%
Net Margin
75.1%
YoY Growth
39.4%
EPS
$2.42
LIGAND PHARMACEUTICALS INC Q4 FY2025 Financial Summary
LIGAND PHARMACEUTICALS INC reported revenue of $59.7M (up 39.4% YoY) for Q4 FY2025, with a net profit of $44.8M (up 244.1% YoY) (75.1% margin).
Key Financial Metrics
| Total Revenue | $59.7M |
|---|---|
| Net Profit | $44.8M |
| Gross Margin | N/A |
| Operating Margin | 23.2% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
LIGAND PHARMACEUTICALS INC Q4 FY2025 revenue of $59.7M breaks down across 4 segments, led by Intangible Royalty Assets at $40.7M (68.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Intangible Royalty Assets | $40.7M | 68.2% |
| Financial Royalty Assets | $9.8M | 16.5% |
| Material Sales Captisol | $7.8M | 13.1% |
| Vaxneuvance | $1.4M | 2.4% |
LIGAND PHARMACEUTICALS INC Revenue by Segment — Quarterly Trend
LIGAND PHARMACEUTICALS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Intangible Royalty Assets and Financial Royalty Assets) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Intangible Royalty Assets | $40.7M | — | $30.1M | $21.6M |
| Financial Royalty Assets | $9.8M | $6.4M | $6.3M | — |
| Material Sales Captisol | $7.8M | $10.7M | — | $13.5M |
| Vaxneuvance | $1.4M | $2.0M | — | — |
LIGAND PHARMACEUTICALS INC Annual Revenue by Year
LIGAND PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $268.1M).
LIGAND PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
LIGAND PHARMACEUTICALS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $59.7M | +39.4% | $44.8M | 75.1% |
| Q3 FY2025 | $115.5M | +122.8% | $117.3M | 101.6% |
| Q2 FY2025 | $47.6M | +14.7% | $4.8M | 10.2% |
| Q1 FY2025 | $45.3M | +46.3% | $-42.5M | -93.6% |
| Q4 FY2024 | $42.8M | +52.4% | $-31.1M | -72.6% |
| Q3 FY2024 | $51.8M | +57.6% | $-7.2M | -13.8% |
| Q2 FY2024 | $41.5M | +57.5% | $-51.9M | -125.0% |
| Q1 FY2024 | $31.0M | -29.6% | $86.1M | 278.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.0M | $41.5M | $51.8M | $42.8M | $45.3M | $47.6M | $115.5M | $59.7M |
| YoY Growth | -29.6% | 57.5% | 57.6% | 52.4% | 46.3% | 14.7% | 122.8% | 39.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $913.9M | $866.4M | $954.9M | $941.8M | $905.4M | $948.6M | $1.48B | $1.56B |
| Liabilities | $107.3M | $91.2M | $113.7M | $111.3M | $109.9M | $120.1M | $526.6M | $543.4M |
| Equity | $806.5M | $775.2M | $841.2M | $830.4M | $795.5M | $828.5M | $950.2M | $1.02B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $18.7M | $13.3M | $36.5M | $28.5M | $-25.4M | $15.8M | $13.1M | $45.9M |